Logo

Genomatica to Develop In Silico Model for Dow Chemical

Sep 18, 2002

NEW YORK, Sept. 18 - Genomatica is developing an in silico model for Dow Chemical to predict the effect of genetic changes on microbial metabolism and bioprocessing, the companies announced today.

 

Genomatica, based in San Diego, will use its SimPheny platform to develop the modeling for Dow, according to the company.

 

Financial details of the agreement were not disclosed, though the company said Dow would provide research support and milestone payments.

Breaking News
The Scan

Study Follows Consequences of Early Confirmatory Trials for Accelerated Approval Indications

Time to traditional approval or withdrawal was shorter when confirmatory trials started prior to accelerated approval, though overall regulatory outcomes remained similar, a JAMA study finds.

Sequencing Study Leads to Vaccine Target in Bacteria Behind Neonatal Meningitis

Researchers eBioMedicine track down potential vaccine targets with transposon sequencing on mutant bacteria causing neonatal meningitis in mouse models of the disease.

Multiple Myeloma Progression Influenced by Immune Microenvironment Expression

Researchers in NPJ Genomic Medicine compare RNA sequencing profiles of 102,207 individual cells in bone marrow samples from 18 individuals with rapid or non-progressing multiple myeloma.

Self-Reported Hearing Loss in Older Adults Begins Very Early in Life, Study Says

A JAMA Otolaryngology — Head & Neck Surgery study says polygenic risk scores associated with hearing loss in older adults is also associated with hearing decline in younger groups.